Stroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?

被引：66

作者：

Jiang, Bolun ^{[1
]}

Zhou, Li ^{[1
]}

Lu, Jun ^{[1
]}

Wang, Yizhi ^{[1
]}

Liu, Chengxi ^{[1
]}

You, Lei ^{[1
]}

Guo, Junchao ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2020年 / 10卷

基金：

中国国家自然科学基金;

关键词：

pancreatic ductal adenocarcinoma; stroma; chemotherapy; tumor microenvironment; nanotherapy; EXTRACELLULAR-MATRIX; HEDGEHOG PATHWAY; STELLATE CELLS; DRUG-DELIVERY; LINE THERAPY; MOUSE MODEL; TUMOR; GEMCITABINE; HYALURONAN; MICROBUBBLES;

D O I：

10.3389/fonc.2020.576399

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic ductal adenocarcinoma (PDAC) is a malignancy with one of the worst prognoses worldwide and has an overall 5-year survival rate of only 9%. Although chemotherapy is the recommended treatment for patients with advanced PDAC, its efficacy is not satisfactory. The dense dysplastic stroma of PDAC is a major obstacle to the delivery of chemotherapy drugs and plays an important role in the progression of PDAC. Therefore, stroma-targeting therapy is considered a potential treatment strategy to improve the efficacy of chemotherapy and patient survival. While several preclinical studies have shown encouraging results, the anti-tumor potential of the PDAC stroma has also been revealed, and the extreme depletion might promote tumor progression and undermine patient survival. Therefore, achieving a balance between stromal abundance and depletion might be the further of stroma-targeting therapy. This review summarized the current progress of stroma-targeting therapy in PDAC and discussed the double-edged sword of its therapeutic effects.

引用

页数：9

共 100 条

[1] Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer [J].

Adiseshaiah, Pavan P. ;

Crist, Rachael M. ;

Hook, Sara S. ;

McNeil, Scott E. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (12) :750-765

[2] Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma [J].

Aguilera, Kristina Y. ;

Huang, Huocong ;

Du, Wenting ;

Hagopian, Moriah M. ;

Wang, Zhen ;

Hinz, Stefan ;

Hwang, Tae Hyun ;

Wang, Huamin ;

Fleming, Jason B. ;

Castrillon, Diego H. ;

Ren, Xiaomei ;

Ding, Ke ;

Brekken, Rolf A. .

MOLECULAR CANCER THERAPEUTICS, 2017, 16 (11) :2473-2485

[3] Unraveling the therapeutic potential of the Hedgehog pathway in cancer [J].

Amakye, Dereck ;

Jagani, Zainab ;

Dorsch, Marion .

NATURE MEDICINE, 2013, 19 (11) :1410-1422

[4] Acridine Orange Conjugated Polymersomes for Simultaneous Nuclear Delivery of Gemcitabine and Doxorubicin to Pancreatic Cancer Cells [J].

Anajafi, Tayebeh ;

Scott, Michael D. ;

You, Seungyong ;

Yang, Xiaoyu ;

Choi, Yongki ;

Qian, Steven Y. ;

Mallik, Sanku .

BIOCONJUGATE CHEMISTRY, 2016, 27 (03) :762-771

[5] Emerging Therapeutic Potential of Nanoparticles in Pancreatic Cancer: A Systematic Review of Clinical Trials [J].

Au, Minnie ;

Emeto, Theophilus I. ;

Power, Jacinta ;

Vangaveti, Venkat N. ;

Lai, Hock C. .

BIOMEDICINES, 2016, 4 (03)

[6] Evaluation of the "Steal" Phenomenon on the Efficacy of Hypoxia Activated Prodrug TH-302 in Pancreatic Cancer [J].

Bailey, Kate M. ;

Cornnell, Heather H. ;

Ibrahim-Hashim, Arig ;

Wojtkowiak, Jonathan W. ;

Hart, Charles P. ;

Zhang, Xiaomeng ;

Leos, Rafael ;

Martinez, Gary V. ;

Baker, Amanda F. ;

Gillies, Robert J. .

PLOS ONE, 2014, 9 (12)

[7] Genomic analyses identify molecular subtypes of pancreatic cancer [J].

Bailey, Peter ;

Chang, David K. ;

Nones, Katia ;

Johns, Amber L. ;

Patch, Ann-Marie ;

Gingras, Marie-Claude ;

Miller, David K. ;

Christ, Angelika N. ;

Bruxner, Tim J. C. ;

Quinn, Michael C. ;

Nourse, Craig ;

Murtaugh, L. Charles ;

Harliwong, Ivon ;

Idrisoglu, Senel ;

Manning, Suzanne ;

Nourbakhsh, Ehsan ;

Wani, Shivangi ;

Fink, Lynn ;

Holmes, Oliver ;

Chin, Vencssa ;

Anderson, Matthew J. ;

Kazakoff, Stephen ;

Leonard, Conrad ;

Newell, Felicity ;

Waddell, Nick ;

Wood, Scott ;

Xu, Qinying ;

Wilson, Peter J. ;

Cloonan, Nicole ;

Kassahn, Karin S. ;

Taylor, Darrin ;

Quek, Kelly ;

Robertson, Alan ;

Pantano, Lorena ;

Mincarelli, Laura ;

Sanchez, Luis N. ;

Evers, Lisa ;

Wu, Jianmin ;

Pinese, Mark ;

Cowley, Mark J. ;

Jones, Marc D. ;

Colvin, Emily K. ;

Nagrial, Adnan M. ;

Humphrey, Emily S. ;

Chantrill, Lorraine A. ;

Mawson, Amanda ;

Humphris, Jeremy ;

Chou, Angela ;

Pajic, Marina ;

Scarlett, Christopher J. .

NATURE, 2016, 531 (7592) :47-+

[8] IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma [J].

Biffi, Giulia ;

Oni, Tobiloba E. ;

Spielman, Benjamin ;

Hao, Yuan ;

Elyada, Ela ;

Park, Youngkyu ;

Preall, Jonathan ;

Tuveson, David A. .

CANCER DISCOVERY, 2019, 9 (02) :282-301

[9] Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer [J].

Borazanci, Erkut ;

Von Hoff, Daniel D. .

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (07) :739-747

[10] A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer [J].

Bramhall, SR ;

Schulz, J ;

Nemunaitis, J ;

Brown, PD ;

Baillet, M ;

Buckels, JAC .

BRITISH JOURNAL OF CANCER, 2002, 87 (02) :161-167

← 1 2 3 4 5 6 7 8 9 10 →